Table 1.
The list of miRNAs which have oncogenic or tumor suppressor activity.
| miRNA | Tested in tumors | Alteration | Targeted genes | References |
|---|---|---|---|---|
| Oncogenic activity | ||||
| miR-21 | Colon, breast, pancreatic, lung, prostate, liver, and gastric cancers | Increase | PTEN, TPM1, Pdcd4, maspin | (Chan et al., 2005; Iorio et al., 2005; Li et al., 2009a; Ribas et al., 2009; Si et al., 2007; Yao et al., 2009) |
| miR-155 | Lung and breast cancers, CLL*, AML* | Increase | AT1R, TP53INP1 | (Gironella et al., 2007; Greither et al., 2009; Habbe et al., 2009; Iorio et al., 2005) |
| miR-17–92 | Lung, breast, colon, gastric, pancreatic cancers, lymphomas | Increase | Tsp1, CTGF, E2F1, AIB1, TGFBR2 | (Diosdado et al., 2009; He et al., 2005; Manni et al., 2009; Northcott et al., 2009; Uziel et al., 2009) |
| miR-106a | Colon and gastric cancers | Increase | RB-1 | (Diaz et al., 2008; Xiao et al., 2009) |
| miR-373 | Testicular tumor, Gastric cancer | Increase | LATS2 | (Lee et al., 2009) |
| miR-197 | Lung cancer | Increase | ACVR1, TSPAN3, FUS1 | (Du et al., 2009) |
| miR-221 | Breast and liver cancers, CLL | Increase | KIT, p27(Kip1), p57, PTEN | (Park et al., 2009a) |
| miR-222 | Breast and liver cancers, CLL | Increase | KIT, p27(Kip1), p57, PTEN | (Greither et al., 2009) |
| miR-372 | Testicular tumor | Increase | LATS2 | (Voorhoeve et al., 2007) |
| Tumor suppressor activity | ||||
| let-7 | Lung, ovarian cancer, breast, and colorectal cancers | Decrease | RAS, PRDM1, HMGA2, c-Myc, E2F, cyclin D2 | (Johnson et al., 2007; Johnson et al., 2005; Lee and Dutta, 2007; Takamizawa et al., 2004) |
| miR-15 miR-16 |
Gastric and lung cancers | Decrease | Bcl-2, Wt-1 | (Calin et al., 2008; Cimmino et al., 2005; Takeshita et al., 2009) |
| miR-34 | Breast, pancreatic, colon cancers | Decrease | E2F3, Notch1, CDK4, CDK5 | (Chang et al., 2007; Corney et al., 2007; Ji et al., 2009b) |
| miR-17-5p | Breast cancer, CLL* | Decrease | AIB1, E2F1, p21, BIM | (Mraz et al., 2009; Robertus et al., 2009) |
| miR-29 | Lung and breast cancers, CLL*, AML* | Decrease | MCL-1, TCL-1, DNMT3s | (Mraz et al., 2009; Park et al., 2009b) |
| miR-124a | ALL*, medulloblastoma | Decrease | CDK6 | (Agirre et al., 2009; Pierson et al., 2008) |
| miR-127 | Breast cancer, lymphoma | Decrease | Bcl-6 | (Robertus et al., 2009) |
| miR-143 | Gastric and prostate cancers | Decrease | Ras, ERK5 | (Chen et al., 2009b; Clape et al., 2009; Takagi et al., 2009) |
| miR-145 | Breast and gastric cancers | Decrease | Mucin1, ERG | (Sachdeva and Mo, 2010; Spizzo et al., 2010; Takagi et al., 2009) |
| miR-181 | Colorectal cancer | Decrease | TCL-1, E2F5, eIF5A | (Pekarsky et al., 2006) |
| miR – 146a | Pancreatic cancer | Decrease | IRAK-1, EGFR | (Li et al., 2010) |
*
CLL, chronic lymphoblastic leukemia; AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia.